Overview

Impact of Hepatitis C Therapy and Bone Health

Status:
Terminated

Trial end date:
2018-11-30

Target enrollment:

Participant gender:

Summary

An evaluation of the impact of Elbasvir and Grazoprevir (EBR/GZR) HCV therapy on the heart risk and bone health of HCV mono-infected and HIV/HCV co-infected patients.

Phase:

Phase 4

Details

Lead Sponsor:

Dallas VA Medical Center

Collaborator:

Merck Sharp & Dohme Corp.

Treatments:

Elbasvir-grazoprevir drug combination